La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Gyre Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Gyre Therapeutics..

Gyre Therapeutics (NASDAQ:GYRE) Azioni, Catena delle Opzioni

Gyre Therapeutics

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics Inc

JP Morgan analyst Brian Essex maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and raises the price target from $40 to $42.

News

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Rapid7, Raises Price Target to $42

Baird analyst Jeff Johnson maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Neutral and lowers the price target from $39 to $37.

TNDM

Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $37

RBC Capital analyst Nik Modi maintains Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) with a Sector Perform and raises the price target from $2.5 to $2.75.

COOK

RBC Capital Maintains Sector Perform on Traeger, Raises Price Target to $2.75

JP Morgan analyst Samik Chatterjee maintains Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) with a Overweight and raises the price target from $195 to $200.

QCOM

JP Morgan Maintains Overweight on Qualcomm, Raises Price Target to $200

AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) offset lower attendance with higher ticket prices and food and beverage revenue to help <a href="https://www.benzinga.com/news/earnings/24/11/41790068/amc-ceo-is-confident-and-optimistic-about-cinema-chains-future-as-q3-earnings-show-revenue-beat-rec">beat third-quarter revenue </a>and earnings per share estimates, which could help the company's recovery an analyst says.
The AMC Analyst: Benchmark analyst Mike Hickey maintained a Hold rating on AMC with no price target.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/11/41778124/amc-q3-earnings-preview-can-deadpool-wolverine-box-office-strength-lift-stock">AMC Q3 Earnings Preview: Can &#8216;Deadpool &amp; Wolverine&#8217; Box Office Strength Lift Stock?</a>
The Analyst Takeaways: AMC showed strategic steps towards growth and a recovery, Hickey said in a new investor note.
The analyst said AMC "exceeded expectations" in the third quarter, including for revenue and adjusted EBITDA.
Attendance was down 11.5% year-over-year in the third quarter, but was offset by higher average revenue per moviegoer.
"Despite this decline, the average ticket price rose by 5.44%, and food and beverage revenue per patron increased by 14.79%," Hickey said.
In the U.S., attendance was down 8.9% year-over-year but offset by higher average ticket prices and a 14.3% increase in food and beverage revenue per patron, Hickey added.
The U.S. segment saw a record for food and beverage revenue per moviegoer in the third quarter.
"These increases reflect AMC's strategic pricing adjustments and enhanced in-theater offerings to maximize per-patron revenue."
Food and beverage revenue per person was up 11.9% in the international segment, also helping to offset attendance weakness.
The analyst highlighted AMC's commentary on being interested in adding more sports content like NCAA Football and NFL games, pending securing rights and exclusivity.
What's Next: Hickey said movie studios are increasing film output, which should help support a "healthier release schedule in 2025 and 2026" for AMC and the movie theater sector.
AMC CEO Adam Aron has been highlighting the strong movie lineup for 2025 and 2026 for many months and shared his optimism for the next two years and the closing quarter of 2024 on Wednesday.
&#8220;We believe of much greater importance is our bullishness about the impressive movie slate that is coming to our theaters in November and December of 2024, and continuing in 2025 and again in 2026,&#8221; Aron said.
On Thursday, AMC <a href="https://x.com/AMCTheatres/status/1854532157756096565">announced </a>the upcoming release of its Cinnamon Butter Microwave Popcorn, which will be available soon in Kroger and Publix stores in the U.S. and online.
AMC Price Action: AMC stock is down 4.7% to $4.36 on Thursday, versus a 52-week trading range of $2.38 to $11.88. AMC stock is down 28% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/41779145/amc-stock-trades-higher-ahead-of-q3-earnings-will-sentiment-shift-for-retail-favorite">AMC Stock Trades Higher Ahead Of Q3 Earnings: Will Sentiment Shift For Retail Favorite?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Entertainment

Reiteration

Trading Ideas

AMC Offsets Lower Q3 Attendance With Higher Ticket Prices, Concessions: Analyst Sees 'Strategic Pricing' Success

Baird analyst Brian Skorney maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and lowers the price target from $200 to $193.

SRPT

Baird Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $193

Mark Cuban, the billionaire entrepreneur and outspoken critic of Donald Trump, has owned a condo in the <a href="https://www.benzinga.com/news/24/04/38184282/peek-inside-trumps-opulent-lifestyle-the-10-most-lavish-assets-he-owns">Trump International Hotel and Tower</a> for almost 25 years – a fact that has come to light recently, thanks to property records obtained by the New York Post. Cuban purchased the 3,700-square-foot luxury apartment in July 2000 for $13.5 million. Despite his public criticisms of Trump, Cuban seems to have held onto this prime piece of New York real estate without much fuss or fanfare.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
</ul>
Located on Central Park West, this spacious condo sits on the 45th floor of the building and boasts four bedrooms, six bathrooms and stunning views of Central Park and the Manhattan skyline. It also includes a formal dining room, a large living area with floor-to-ceiling windows, a breakfast nook and a private library. One gets a real taste of high-end New York luxury here – not to mention access to amenities like a five-star health club, pool, spa and room service from Michelin-starred Jean-Georges.
The purchase, made under &#8220;The Radical Revocable Trust,&#8221; a company Cuban oversees, includes access to all the shared luxuries at 1 Central Park West. From valet parking to 24-hour door attendants and concierge services, Cuban&#8217;s apartment offers the works. However, it's unclear how often Cuban actually uses the property or enjoys these high-end perks.
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
Cuban has been open about his dislike for Trump, especially since Trump took office. It's well known that Cuban initially supported Trump's presidential run in 2016, saying that Trump brought something different to politics by <a href="https://www.benzinga.com/news/24/09/40849505/mark-cuban-says-he-truly-does-not-hate-trump-but-calls-him-a-lousy-president-if-he-wasnt-running">not being a &#8220;typical candidate.&#8221;</a>
However, their relationship soured as Trump's time in office progressed, with Cuban saying that discussions with Trump never worked when they involved details. Despite this, Cuban worked with Trump – notably during the COVID-19 pandemic – because, as he put it, it was about &#8220;country over party.&#8221;
See Also: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
In recent years, Cuban has turned his support to Vice President Kamala Harris and he's been seen <a href="https://www.benzinga.com/startups/24/10/41490405/at-an-arizona-town-hall-mark-cuban-assures-that-harris-wont-tax-unrealized-gains-if-hes-wrong-hell-w">actively campaigning for her</a>. He has even admitted that he hasn't donated to any political campaign since 2001, which adds another layer of irony to the fact that he still owns this Trump Tower apartment.
In a comment to the Daily Mail, Cuban mentioned that the property value has actually dropped significantly since he bought it. While there was once interest in the apartment for $33 million in 2014, by 2018, the best offer he received was less than half of that. This might help explain why he still owns it – he simply hasn't been able to get the price he wants for it.
For someone so <a href="https://www.benzinga.com/news/24/09/40869372/mark-cuban-calls-out-trumps-investment-record-which-startups-has-trump-ever-invested-in-that-didnt-i">publicly at odds with Trump</a>, it&#8217;s interesting that Cuban still holds onto a slice of Trump-branded luxury real estate. Perhaps it&#8217;s just a savvy business decision or a reminder that sometimes business and politics don&#8217;t mix the way people expect.
Read Next:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Real Estate

Mark Cuban Has Quietly Owned A Trump Tower Apartment Since 2000. His Secret $13.5 Million Purchase Just Came To Light

JP Morgan analyst Pablo Singzon maintains Palomar Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMR#NASDAQ">PLMR</a>) with a Neutral and raises the price target from $93 to $100.

PLMR

JP Morgan Maintains Neutral on Palomar Hldgs, Raises Price Target to $100

RBC Capital analyst Ken Herbert maintains VSE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEC#NASDAQ">VSEC</a>) with a Outperform and raises the price target from $120 to $125.

VSEC

RBC Capital Maintains Outperform on VSE, Raises Price Target to $125

Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) shares are trading higher on Thursday. The company partnered with Infineon Technologies AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IFNNY#OTC">IFNNY</a>) to develop the power architecture for its electric vehicles, supporting the goal of providing clean, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41805368/infineon-and-stellantis-team-up-to-advance-innovation-in-power-conversion-and-distribution-for-nex" rel="noreferrer noopener">safe, and affordable mobility</a>.
As per the deal, Stellantis and Infineon Technologies have signed significant supply and capacity agreements to lay the foundation for their collaboration on next-generation power architecture.
The collaboration includes Infineon&#8217;s PROFET smart power switches to replace fuses, SiC semiconductors to enhance EV performance and reduce costs, and AURIX microcontrollers for the STLA Brain zonal architecture.
Peter Schiefer, President of Infineon&#8217;s Automotive Division said, &#8220;As the world&#8217;s leading automotive semiconductor vendor, we bring our product-to-system expertise and dependable electronics to the table. Our semiconductors drive the decarbonization and digitalization of mobility. They increase the efficiency of cars and enable software-defined architectures that will significantly improve the user experience.&#8221;
Last month, Stellantis reported a 27%&nbsp;decline in third-quarer net revenues, primarily due to lower shipments and unfavorable mix <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41645224/stellantis-reports-lower-q3-2024-net-revenues-amid-transitional-period-of-product-upgrades-and-inv" rel="noreferrer noopener">as well as pricing and foreign exchange impacts.</a>
Price Action: STLA shares are up 1.23% at $14.04 at the last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers" target="_blank" rel="noreferrer noopener">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a></li>
</ul>

Equities

Large Cap

Contracts

IFNNY

STLA

Stellantis And Infineon Forge Partnership For Future EV Power Solutions: Details

Baird analyst Brian Skorney maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Neutral and raises the price target from $80 to $95.

GILD

Baird Maintains Neutral on Gilead Sciences, Raises Price Target to $95

WIIM

MDAI

Spectral AI shares are trading lower. The company reported Q3 financial results.

JP Morgan analyst Seth Seifman maintains Mercury Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) with a Neutral and raises the price target from $36 to $40.

MRCY

JP Morgan Maintains Neutral on Mercury Sys, Raises Price Target to $40

APVO

Aptevo Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.

Electric vehicle company Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) could provide an update on production and delivery guidance and share the impact the 2024 election outcome has on the company's future when third-quarter financial results are reported Thursday<a href="https://www.benzinga.com/earnings"> after market close.</a>
Earnings Estimates: Analysts expect Rivian to report third-quarter revenue of $1.00 billion, according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The revenue forecast is below last year's third-quarter total of $1.34 and would be the company's lowest revenue total in six quarters.
Rivian has beaten analyst estimates for revenue in six straight quarters and seven of the past 10 quarters overall.
Analysts expect the company to report a loss of 92 cents per share, compared to a loss of $1.19 in last year's third quarter. The company has beaten analyst estimates for earnings per share in eight straight quarters.
What Analysts Are Saying: Softness in demand is a key area JPMorgan analyst Ryan Brinkman is <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41460886/rivian-analyst-cuts-estimates-on-demand-concerns-warns-softer-production-delivery-t">watching in the company's </a>third-quarter financial report and commentary.
The analyst has an Underweight rating on Rivian and recently lowered the price target from $14 to $12.
Brinkman's update came after Rivian <a href="https://www.benzinga.com/markets/equities/24/10/41182921/rivians-production-forecast-hits-bump-supply-shortage-sends-shares-tumbling">lowered its annual production guidance </a>to a range of 47,000 to 49,000 vehicles, down from a previous guidance of 57,000 vehicles.
The change came due to a shortage in a component that is disrupting production, according to the company.
"Interestingly, 2024 full-year deliveries guidance was reiterated at ~50-52K despite the production shortfall, implying unchanged demand, although we note that the softer deliveries in 3Q do not on the surface appear supply-related," Brinkman said.
Rivian added 3,139 units to its inventory in the third quarter, marking one of the company's largest quarterly adds. The figure was higher than an average quarterly change of around 950 units, the analyst said, which could suggest soft demand.
"The softer trend to production (and possibly deliveries also) we think could endanger the company&#8217;s still growth stock multiple."
Here are other recent <a href="https://www.benzinga.com/quote/RIVN/analyst-ratings">analyst ratings for Rivian</a> and their price targets:
<ul>
<li>Guggenheim: Maintained a Buy rating and lowered the price target from $21 to $18</li>
<li>Mizuho: Maintained a Neutral rating and lowered the price target from $15 to $12</li>
<li>Truist: Maintained a Hold rating and lowered the price target from $16 to $12</li>
<li>Barclays: Maintained an Equal-Weight rating and lowered the price target from $16 to $13</li>
<li>Wells Fargo: Maintained an Equal-Weight rating and lowered the price target from $15 to 11</li>
</ul>
Key Items to Watch: Rivian's quarterly report will mark one of the first automotive companies to present earnings and comments after the 2024 election.
Rivian<a href="https://www.benzinga.com/news/24/11/41784487/rivian-lucid-stocks-sink-after-trump-win-whats-driving-bearish-move"> stock fell Wednesday </a>in the aftermath of Donald Trump winning the 2024 presidential election. While it's possible Rivian won't address the matte, analysts and investors would like to hear if the new presidency could hurt the overall electric vehicle company and what Rivian will be doing to address the concerns.
The election win by Trump comes as Rivian faces a crossroads of increasing production capabilities ahead of the R2 launch planned for 2026 and could see lower production and delivery figures ahead of new vehicles.
Another item Rivian may not address would be the competition from companies like Tesla. Rivian was<a href="https://www.benzinga.com/news/24/10/41431406/elon-musk-says-tesla-will-not-buy-ev-rival-rivian-going-to-have-a-hard-time"> mentioned as a buyout candidate</a> to Tesla CEO Elon Musk, but he said the company wasn't interested and suggested potential struggles ahead.
"Rivian's going to have a hard time," Musk said.
Musk previously predicted in February 2024 that Rivian had around six quarters before it went bankrupt.
A joint venture with Volkswagen (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>) worth up to $5 billion could help Rivian's financials. Investors and analysts could also get an update on this joint venture Thursday.
RIVN Price Action: Rivian stock is up 5.07% to $10.20 on Thursday versus a 52-week trading range of $8.26 to $24.61. Rivian stock is down 53% year-to-date in 2024.
Read Next: • <a href="https://www.benzinga.com/news/24/10/41325252/tesla-cybertruck-leads-the-pack-as-most-popular-ev-truck-in-us-in-q3-outselling-rivals-from-ford-gm">Tesla Cybertruck Leads The Pack As Most Popular EV Truck In US In Q3, Outselling Rivals From Ford, GM And Rivian Combined</a>
Photo: Shutterstock

Previews

RIVN

VWAGY

Rivian Q3 Earnings Preview: Analyst Worries About Demand, Will Company Comment On 2024 Election Impact?

JP Morgan analyst Mark Murphy maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Overweight and raises the price target from $560 to $635.

HUBS

JP Morgan Maintains Overweight on HubSpot, Raises Price Target to $635

Baird analyst David Rodgers maintains Cencora (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) with a Outperform and raises the price target from $287 to $292.

Baird Maintains Outperform on Cencora, Raises Price Target to $292

RBC Capital analyst Sean Dodge maintains Waystar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>) with a Outperform and raises the price target from $31 to $34.

RBC Capital Maintains Outperform on Waystar Holding, Raises Price Target to $34

JP Morgan analyst Ken Worthington maintains Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) with a Neutral and raises the price target from $134 to $175.

HLNE

JP Morgan Maintains Neutral on Hamilton Lane, Raises Price Target to $175

On Thursday, Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) reported third-quarter revenue of $1.03 billion, a decrease of 4% on a reported basis or a 1% organic constant currency growth, in line with the consensus.
The animal health company reported adjusted EPS of $0.13, down 28% year over year, beating the consensus of $0.12.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40959456/elancos-dermatology-treatment-secures-fda-approval-for-itchy-dogs-analyst-highlight" rel="noreferrer noopener">Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy</a>
Pet Health revenue was $486 million, a decrease of 2% on a reported and constant currency basis, primarily driven by competitive pressure on certain products in the U.S. veterinary channel, competitive pressure in Australia, and supply volatility for vaccines in the U.S., partially offset by increased sales of new products and improved demand for retail parasiticide products in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41801193/elanco-animal-health-reports-third-quarter-2024-results" rel="noreferrer noopener">the U.S. and Europe</a>.
Farm Animal revenue fell 6% (+3% on constant currency) to $530 million, driven by a 3% increase in price. Volumes were flat, primarily driven by strength in U.S. cattle, led by Experior and Rumensin, and poultry sales in the U.S. and Europe, offset by lower demand for sheep products in Australia and planned volume declines from the strategic decision to change go-to-market models in certain countries, as well as the European recall of Kexxtone.
Gross profit was $538 million, or a margin of 52.2%, with a 220-basis point decline driven by higher inflation, unfavorable manufacturing performance, and product mix associated with the divested aqua business, partially offset by increased pricing.
Guidance: Elanco tightened its financial guidance for the full year 2024.
The company expects 2024 sales of $4.42 billion-$4.45 billion versus prior guidance of $4.41 billion-$4.46 billion and consensus of $4.43 billion.
The company expects 2024 adjusted EPS of $0.89-$0.95, compared to previous guidance of $0.88-$0.96 and the consensus of $0.92. Elanco has lowered expectations for U.S. Pet Health parasiticides.
Elanco expects fourth-quarter sales of $1 billion—$1.03 billion and adjusted EPS of $0.13-$0.18, compared to the consensus of $1.034 billion and $0.12, respectively.
"We are encouraged by the acceleration of constant currency sales growth from 1% in 2023 to the expected 3% organic constant currency growth in 2024. We see this accelerating further to mid-single digits in 2025 with increased sales from new products and a stabilizing base driving expected growth in both pet health and farm animal," said Todd Young, CFO of Elanco.
Price Action: ELAN stock is up 13.10% at $14.55 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41812662/krispy-kreme-falters-in-q3-earnings-miss-sales-slide-and-outlook-dims-post-insomnia-cookies-sale" target="_blank" rel="noreferrer noopener">Krispy Kreme Falters In Q3: Earnings Miss, Sales Slide, And Outlook Dims Post-Insomnia Cookies Sale</a></li>
</ul>
Image via Pexels

Earnings

Guidance

Health Care

Movers

General

ELAN

Elanco Animal Q3 Earnings: Profit Beat, New Products And Stabilized Business To Drive 2025 Sales

Gyre Therapeutics announces expected addition to Russell 2000 and Russell 3000 Indexes

Gyre Therapeutics files to sell 1.08M shares of common stock for holders

Gyre Therapeutics (GYRE) has issued an announcement. Gyre Therapeutics has announced the approval of its IND application by China's CDE for F230 ta...

Gyre Therapeutics Advances with F230 IND Approval in China

Suzhou MediLink partnered with Germany's BioNTech to use MediLink's TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in milestones, plus tiered royalties.

Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership

Week In Review: MediLink And BioNTech Form $1.8B ADC Partnership

Gyre Therapeutics (GYRE) has shared an announcement. Gyre Therapeutics, Inc. has reported a vacancy on its Audit Committee following the resignatio...

Gyre Therapeutics Seeks Compliance Amid Board Reshuffle

Gyre Therapeutics (GYRE) has issued an announcement. Gyre Therapeutics, Inc. has strengthened its leadership by appointing the highly experienced D...

Gyre Therapeutics Welcomes Dr. Epstein to Leadership Team

Gyre Therapeutics Non-GAAP EPS of $0.01, revenue of $25.2M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Gyre Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gyre-stock-quote/">GYRE</a>) just reported results for the second quarter of 2024.<ul><li>Gyre Therapeutics reported earnings per share of 1 cent.</li><li>The company reported revenue of $25.23 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/gyre-stock-earnings-gyre-therapeutics-for-q2-of-2024/">GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024

Gyre Therapeutics (GYRE) announced that the last patient in Gyre Pharmaceuticals' pivotal Phase 3 trial in the People's Republic of China or PRC ev...

Comments

Gyre Therapeutics

Gyre Therapeutics (GYRE) Opzioni

Gyre Therapeutics (NASDAQ:GYRE) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO